Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study

BACKGROUND AND AIMS: The risk of use of immune-mediated diarrhea and colitis (imDC) in patients with preexisting inflammatory bowel disease (IBD) is not fully understood. We report the incidence of imDC in these patients, and compare with a matched cohort of patients with cancer and without IBD. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Sleiman, Joseph, Wei, Wei, Shah, Ravi, Faisal, Muhammad Salman, Philpott, Jessica, Funchain, Pauline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220461/
https://www.ncbi.nlm.nih.gov/pubmed/34158318
http://dx.doi.org/10.1136/jitc-2021-002567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220461/
https://www.ncbi.nlm.nih.gov/pubmed/34158318
http://dx.doi.org/10.1136/jitc-2021-002567

Ejemplares similares